Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 12/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164264 | 0.85 | KCNA5 (0.56) | KCNA5KCNH2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4379312 | 0.80 | KCNA5 (0.50) | KCNA5KCNH2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3934300 | 0.75 | ALDH1A1 (0.54) | KCNA5KCNH2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3757650 | 0.73 | KCNA5 (0.80) | KCNA5KCNH2 | |
| SCHEMBL3761018 | 0.72 | KCNA5 (0.80) | KCNA5KCNH2 | |
| SCHEMBL3762773 | 0.72 | KCNA5 (0.80) | KCNA5KCNH2 | |
| SCHEMBL3930978 | 0.71 | KCNA5 (0.49) | KCNA5KCNH2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3751028 | 0.71 | KCNA5 (0.84) | KCNA5KCNH2 | |
| SCHEMBL3745328 | 0.70 | KCNA5 (1.00) | KCNA5KCNH2 | |
| SCHEMBL3931555 | 0.70 | ALDH1A1 (0.69) | KCNA5KCNH2ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291983-A1 | 3-Oxoisoindoline-1-Carboxamide Derivatives as Analgesic Agents | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | US | claimed |
| US-20090291983-A1 | 3-Oxoisoindoline-1-Carboxamide Derivatives as Analgesic Agents | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291983-A1 | 3-Oxoisoindoline-1-Carboxamide Derivatives as Analgesic Agents | OPRD1, OPRK1, OPRM1 | KCNA5 536/4885KCNH2 204/4885PRMT5 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.